ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY

Hematological Oncology ◽

10.1002/hon.1_2632 ◽

2019 ◽

Vol 37 ◽

pp. 555-556

Author(s):

A.J. Davies ◽

O. Tansley Hancock ◽

T. Cummin ◽

J. Caddy ◽

L. Stanton ◽

...

Keyword(s):

B Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

High Dose ◽

High Dose Therapy ◽

Dose Therapy ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

Haematologica ◽

10.3324/haematol.2013.090597 ◽

2013 ◽

Vol 98 (11) ◽

pp. 1726-1731 ◽

Cited By ~ 65

Author(s):

N. Mounier ◽

T. El Gnaoui ◽

H. Tilly ◽

D. Canioni ◽

C. Sebban ◽

...

Keyword(s):

B Cell ◽

Phase Ii ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

High Dose ◽

High Dose Therapy ◽

Dose Therapy ◽

Large B Cell Lymphoma ◽

Study Association ◽

Large B Cell

Download Full-text

Non-Hodgkin's lymphoma: Role of high-dose therapy in diffuse large B-cell lymphoma

Annals of Oncology ◽

10.1093/annonc/11.suppl_3.117 ◽

2000 ◽

Vol 11 ◽

pp. 117-122 ◽

Cited By ~ 2

Author(s):

Thomas Cerny ◽

Daniel Betticher

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Hodgkin's Lymphoma ◽

High Dose ◽

High Dose Therapy ◽

Dose Therapy ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study

Leukemia & Lymphoma ◽

10.1080/10428194.2021.1998483 ◽

2021 ◽

pp. 1-9

Author(s):

Guillaume Aussedat ◽

Delphine Maucort-Boulch ◽

Philippe Rey ◽

Violaine Safar ◽

Lionel Karlin ◽

...

Keyword(s):

Retrospective Study ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Salvage Treatment ◽

High Dose ◽

High Dose Therapy ◽

Dose Therapy ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Rituximab plus gemcitabine and oxaliplatine (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.8011 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 8011-8011 ◽

Cited By ~ 1

Author(s):

T. EL Gnaoui ◽

H. Tilly ◽

N. Mounier ◽

C. Gisselbrecht ◽

C. Sebban ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

High Dose ◽

High Dose Therapy ◽

Dose Therapy ◽

Large B Cell Lymphoma ◽

Gela Study ◽

Large B Cell

Download Full-text

Clinical Efficacy and Epigenetic Biomarkers in a Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

SSRN Electronic Journal ◽

10.2139/ssrn.3532538 ◽

2020 ◽

Author(s):

Mu-Chen Zhang ◽

Peng-Peng Xu ◽

Ying Fang ◽

Li Wang ◽

Shu Cheng ◽

...

Keyword(s):

Elderly Patients ◽

B Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Newly Diagnosed ◽

Epigenetic Biomarkers ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)

Hematological Oncology ◽

10.1002/hon.28_2879 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

J Duell ◽

K. J Maddocks ◽

E González‐Barca ◽

W Jurczak ◽

A. M Liberati ◽

...

Keyword(s):

B Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study

British Journal of Haematology ◽

10.1111/bjh.13234 ◽

2014 ◽

Vol 168 (6) ◽

pp. 824-834 ◽

Cited By ~ 8

Author(s):

Sebastian Kirschey ◽

Thomas Flohr ◽

Hans H. Wolf ◽

Norbert Frickhofen ◽

Martin Gramatzki ◽

...

Keyword(s):

Multicentre Study ◽

B Cell ◽

Phase Ii ◽

Salvage Therapy ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

High Dose ◽

High Dose Therapy ◽

Dose Therapy

Download Full-text

RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION

Biomedical Papers ◽

10.5507/bp.2009.035 ◽

2009 ◽

Vol 153 (3) ◽

pp. 211-214 ◽

Cited By ~ 5

Author(s):

Tomas Papajik ◽

Zuzana Pikalova ◽

Ludek Raida ◽

Ivana Skoumalova ◽

Jana Vondrakova ◽

...

Keyword(s):

Stem Cell ◽

B Cell ◽

Cell Lymphoma ◽

Autologous Transplantation ◽

B Cell Lymphoma ◽

High Dose ◽

High Dose Therapy ◽

Large B Cell Lymphoma ◽

Cell Mobilization ◽

Large B Cell

Download Full-text

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy

The Oncologist ◽

10.1634/theoncologist.2019-0286 ◽

2019 ◽

Vol 24 (8) ◽

pp. 1035 ◽

Cited By ~ 3

Author(s):

Ian W. Flinn ◽

Jack Erter ◽

Davey B. Daniel ◽

Joseph R. Mace ◽

Jesus G. Berdeja

Keyword(s):

Elderly Patients ◽

B Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Newly Diagnosed ◽

Chop Chemotherapy ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Preliminary results of a phase II study using response-adapted therapy for limited-stage diffuse large B-cell lymphoma based on interim PET/CT

Hematological Oncology ◽

10.1002/hon.2439_34 ◽

2017 ◽

Vol 35 ◽

pp. 301-302

Author(s):

F. Lv ◽

Z. Xia ◽

K. Xue ◽

Q. Zhang ◽

D. Ji ◽

...

Keyword(s):

B Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Preliminary Results ◽

Interim Pet ◽

Large B Cell Lymphoma ◽

Pet Ct ◽

Large B Cell

Download Full-text